June 27, 2017 9:22 PM ET


Company Overview of Allakos Inc.

Company Overview

Allakos Inc., a biotechnology company, develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos Inc. was founded in 2012 and is based in San Carlos, California.

75 Shoreway Road

Suite A

San Carlos, CA 94070

United States

Founded in 2012



Key Executives for Allakos Inc.

Founder, Chief Executive Officer, President and Director
Co-Founder and Vice President of Research
Chief Medical Officer
Age: 55
Chief Business Officer
Compensation as of Fiscal Year 2016.

Allakos Inc. Key Developments

Allakos Expands License Agreement with The Johns Hopkins University School of Medicine

Allakos Inc. announced the expansion of a license agreement with The Johns Hopkins University relating to the intellectual property of Siglec-8, a potential therapeutic target for a variety of diseases related to inflammation and fibrosis, and antibodies to Siglec-8. Under the expanded agreement, Allakos has exclusive rights to The Johns Hopkins University School of Medicine patents and intellectual property covering antibodies to Siglec-8 for therapeutic or diagnostic use.

Allakos Appoints Steven P. James to the Board of Directors

Allakos announced the appointment of Steven P. James to the Allakos Board of Directors. Mr. James is also Executive Chairman and Chief Executive Officer of Precision Immune Inc., and was the President, CEO, and Director of Labrys Biologics Inc. from December 2012 until it was acquired by Teva Pharmaceuticals in July 2014.

Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis

Allakos Inc. announced it has initiated dosing of AK002 in a Phase 1 clinical trial in patients with systemic mastocytosis. The open-label, single ascending-dose study, being conducted in Germany, will evaluate the safety, tolerability and pharmacokinetics of AK002 and will also offer the opportunity to assess markers of activity. AK002 is a therapeutic antibody intended for the treatment of severe diseases characterized by excess activity of mast cells and eosinophils. Allakos is also conducting a Phase I healthy volunteer study with AK002 to further test the safety, pharmacokinetics and pharmacodynamics of this antibody. The study is anticipated to enroll up to 48 subjects.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Allakos Inc., please visit www.allakos.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.